5.0-header-iStock-938438758

Choose GELSYN-3 with confidence for your patients^³⁵

In a clinical trial, fewer treatment-related adverse events were reported with GELSYN-3 compared to Synvisc.³⁵

93% – 97% of patients and investigators scored the global tolerability as good or very good.
GELSYN-3 patients showed a 37% reduction in pain medication use.
The most common adverse event with GELSYN-3 was injection site pain (0.5%)

3.3-header-iStock-979441902

GELSYN-3 performed as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.³⁵